CASE REPORTS
JOURNAL ARTICLE
Add like
Add dislike
Add to saved papers

Cronkhite-Canada syndrome: a report of two familial cases.

Cronkhite-Canada syndrome (CCS) is a rare syndrome first described in 1955. Since then, over 400 cases worldwide have been reported in the literature. The disease is characterized by diffuse gastrointestinal polyposis, dystrophic changes of the fingernails, alopecia, cutaneous hyperpigmentation, diarrhea, weight loss, and abdominal pain. An autoimmune etiology is suspected. The workup is based on history and physical examination, imaging, and endoscopy with biopsy to confirm gastrointestinal polyposis. Nutritional support and corticosteroids are the mainstay of treatment. Here, we describe two familial cases-one a 50-year-old male patient with chronic diarrhea and epigastric pain since 1.5 years with hyperpigmentation of the hand and foot, alopecia, anorexia, hypogeusia, and weight loss; other case was his 22-year-old son who was asymptomatic, with mild alopecia and hyperpigmentation over his face and hands. Gastrointestinal endoscopy showed multiple polyps in both the cases.

Full text links

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app